Advertisement
Screener

United Therapeutics Corporation (UTHR) Graph

UTHR Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $783.30M; Cost of revenue $99.50M; Research and development $146.30M; Selling, general and administrative $206.70M.
  • 2026-03-31: Revenue $781.50M; Cost of revenue $133.40M; Research and development $138.20M; Selling, general and administrative $184.10M.
  • 2025-12-31: Revenue $790.20M*; Cost of revenue $103.40M*; Research and development $139.50M*; Selling, general and administrative $190.60M*.
  • 2025-09-30: Revenue $799.50M; Cost of revenue $100.90M; Research and development $127.50M; Selling, general and administrative $182.60M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

UTHR revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product AndService Other$6.80MAdcirca$6.70MNebulized Tyvaso$126.00MOrenitram$125.70MRemodulin$126.30MTyvaso DPI$326.60MTyvaso$452.60MUnituxin$65.20MRevenue$783.30MCost of revenue$99.50MGross profit$683.80MOperating income$330.80MOther income, net$13.30MResearch & development$146.30MSelling, general& administrative$206.70MPre-tax income$372.70MIncome tax$39.70MNet income$333.00M

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

UTHR revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Non Us$49.70MUS$733.60MRevenue$783.30MCost of revenue$99.50MGross profit$683.80MOperating income$330.80MOther income, net$13.30MResearch & development$146.30MSelling, general& administrative$206.70MPre-tax income$372.70MIncome tax$39.70MNet income$333.00M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$783.30M$99.50M$146.30M$206.70M$39.70M$333.00M
2026-03-31$781.50M$133.40M$138.20M$184.10M$43.40M$274.90M
2025-12-31$790.20M*$103.40M*$139.50M*$190.60M*$79.70M*$364.30M*
2025-09-30$799.50M$100.90M$127.50M$182.60M$99.30M$338.70M
2025-06-30$798.60M$87.60M$134.00M$212.50M$98.90M$309.50M
2025-03-31$794.40M$92.50M$149.00M$170.10M$101.30M$322.20M
2024-09-30$748.90M$83.10M$103.50M$219.20M$79.50M$309.10M
2024-06-30$714.90M$77.80M$139.60M$177.60M$77.20M$278.10M
2024-03-31$677.70M$72.90M$104.10M$144.40M$92.00M$306.60M
2023-09-30$609.40M$70.10M$84.70M$127.60M$84.20M$267.60M
2023-06-30$596.50M$64.10M$89.00M$130.00M$76.00M$259.20M
2023-03-31$506.90M$52.30M$82.90M$87.30M$51.00M$240.90M
2022-09-30$516.00M$37.20M$66.10M$98.40M$73.20M$239.30M
2022-06-30$466.90M$29.70M$93.90M$141.50M$34.60M$116.00M
2022-03-31$461.90M$25.90M$69.00M$79.00M$68.80M$239.90M
2021-09-30$444.70M$27.70M$79.20M$109.10M$41.70M$162.70M
2021-06-30$446.50M$37.20M$74.30M$112.80M$43.90M$172.60M
2021-03-31$379.10M$23.00M$303.70M(m)$4.20M$28.30M
2020-09-30$380.10M$24.00M$68.70M(m)$47.80M$171.20M
2020-06-30$362.00M$25.90M$89.70M(m)$26.80M$107.10M
2020-03-31$356.30M$23.40M$73.20M(m)$33.90M$137.70M
2019-12-31$311.10M$28.80M(m)(m)(m)(m)
2019-09-30$401.50M$33.00M$85.70M(m)$34.50M$132.40M
2019-06-30$373.60M$26.70M$85.90M(m)$45.30M$205.10M
2019-03-31$362.60M$29.10M$897.40M(m)-$156.00M(m)
2018-12-31$381.40M$31.90M(m)(m)(m)(m)
2018-09-30$412.70M$51.90M$101.10M(m)$33.60M(m)
2018-06-30$444.50M$61.70M$82.30M(m)$45.00M(m)
2018-03-31$389.20M$53.20M$35.70M(m)$64.50M(m)
2017-12-31$464.70M$53.00M(m)(m)(m)(m)
2017-09-30$445.50M$19.50M(m)$47.20M$44.40M(m)
2017-06-30$444.60M$18.90M(m)$67.40M$100.20M(m)
2017-03-31$370.50M$14.30M(m)$56.40M$85.00M(m)
2016-12-31$409.00M(m)(m)(m)(m)(m)
2016-09-30$408.20M(m)$45.90M$100.10M$77.30M(m)
2016-06-30$412.60M(m)(m)$72.20M$79.60M(m)
2016-03-31$369.00M(m)(m)$5.00M$128.40M(m)
2015-12-31$404.90M(m)(m)(m)(m)(m)
2015-09-30$386.20M(m)$9.60M(m)$272.40M(m)
2015-06-30$347.20M(m)$49.41M$110.00M$69.20M(m)
2015-03-31$327.50M(m)$110.21M$211.30M-$200.00K(m)
2014-12-31$346.36M(m)(m)(m)(m)(m)
2014-09-30$329.95M(m)$118.88M$202.51M-$10.60M(m)
2014-06-30$322.80M(m)$39.74M$68.03M$61.18M(m)
2014-03-31$289.40M(m)$12.45M$30.21M$75.69M(m)
2013-12-31$289.02M(m)(m)(m)(m)(m)
2013-09-30$302.23M(m)$72.75M$94.11M$38.49M(m)
2013-06-30$280.61M(m)$54.62M$71.36M$38.66M(m)
2013-03-31$245.14M(m)$50.43M$71.36M$28.51M(m)
2012-12-31$243.82M(m)(m)(m)(m)(m)
2012-09-30$242.47M(m)$65.16M$68.63M$30.38M(m)
2012-06-30$225.58M(m)$37.10M$53.26M$30.97M(m)
2012-03-31$204.21M(m)$33.66M$39.79M$33.18M(m)
2011-12-31$195.18M(m)(m)(m)(m)(m)
2011-09-30$201.74M(m)$59.43M$16.66M$17.64M(m)
2011-06-30$183.75M(m)$24.24M$23.86M$35.72M(m)
2011-03-31$162.51M(m)$47.71M$58.26M$12.45M(m)
2010-12-31$163.69M(m)(m)(m)(m)(m)
2010-09-30$168.57M(m)$40.34M$45.59M$18.22M(m)
2010-06-30$134.72M(m)$28.59M$29.65M$19.34M(m)
2010-03-31$125.91M(m)$34.87M$46.88M$9.75M(m)
2009-09-30$97.22M(m)$31.55M$41.17M-$2.89M(m)
2009-06-30$83.98M(m)$28.65M$49.37M-$3.20M(m)

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$1.56B$232.90M$284.50M$390.80M$83.10M$607.90M
2025-06-30$1.59B$180.10M$283.00M$382.60M$200.20M$631.70M
2024-06-30$1.39B$150.70M$243.70M$322.00M$169.20M$584.70M
2023-06-30$1.10B$116.40M$171.90M$217.30M$127.00M$500.10M
2022-06-30$928.80M$55.60M$162.90M$220.50M$103.40M$355.90M
2021-06-30$825.60M$60.20M$378.00M$230.00M$48.10M$200.90M
2020-06-30$718.30M$49.30M$162.90M(m)$60.70M$244.80M
2019-06-30$736.20M$55.80M$983.30M(m)-$110.70M-$289.50M
2018-06-30$833.70M$114.90M$118.00M(m)$109.50M(m)
2017-06-30$815.10M$33.20M(m)$123.80M$185.20M(m)
2016-06-30$781.60M(m)(m)$77.20M$208.00M(m)
2015-06-30$674.70M(m)$159.62M$321.30M$69.00M(m)
2014-06-30$612.21M(m)$52.19M$98.25M$136.87M(m)
2013-06-30$525.74M(m)$105.05M$142.72M$67.17M(m)
2012-06-30$429.79M(m)$70.76M$93.05M$64.15M(m)
2011-06-30$346.26M(m)$71.95M$82.12M$47.62M(m)
2010-06-30$260.63M(m)$63.05M$75.11M$29.11M(m)
2009-06-30$163.71M(m)$49.60M$78.59M$3.60M(m)

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$2.39B$281.00M$410.50M$565.20M$299.50M$970.40M
2024-09-30$2.14B$233.80M$347.20M$541.20M$248.70M$893.80M
2023-09-30$1.71B$186.50M$256.60M$344.90M$211.20M$767.70M
2022-09-30$1.44B$92.80M$229.00M$318.90M$176.60M$595.20M
2021-09-30$1.27B$87.90M$457.20M$339.10M$89.80M$363.60M
2020-09-30$1.10B$73.30M$231.60M(m)$108.50M$416.00M
2019-09-30$1.14B$88.80M$1.07B(m)-$76.20M-$157.10M
2018-09-30$1.25B$166.80M$219.10M(m)$143.10M(m)
2017-09-30$1.26B$52.70M(m)$171.00M$229.60M(m)
2016-09-30$1.19B(m)$80.70M$177.30M$285.30M(m)
2015-09-30$1.06B(m)$169.20M$304.00M$341.40M(m)
2014-09-30$942.16M(m)$171.07M$300.75M$126.28M(m)
2013-09-30$827.97M(m)$177.80M$236.83M$105.66M(m)
2012-09-30$672.26M(m)$135.91M$161.67M$94.53M(m)
2011-09-30$548.00M(m)$131.38M$98.78M$65.07M(m)
2010-09-30$429.21M(m)$103.39M$120.70M$47.33M(m)
2009-09-30$260.93M(m)$81.16M$119.76M$708.00K(m)

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$3.18B$384.40M$550.00M$755.80M$379.20M$1.33B
2024-12-31$2.88B$309.70M$481.00M$709.70M$343.90M$1.20B
2023-12-31$2.33B$257.50M$408.00M$477.10M$289.50M$984.80M
2022-12-31$1.94B$151.60M$322.90M$482.10M$223.30M$727.30M
2021-12-31$1.69B$122.50M$540.10M$467.00M$118.10M$475.80M
2020-12-31$1.48B$108.10M$357.70M(m)$124.10M(m)
2019-12-31$1.45B$117.60M$1.18B(m)-$60.50M(m)
2018-12-31$1.63B$198.70M$357.90M$265.80M$169.70M(m)
2017-12-31$1.73B$105.70M$264.60M$330.10M$351.60M(m)
2016-12-31$1.60B$72.70M$147.60M$316.80M$346.50M(m)
2015-12-31$1.47B(m)$245.10M$452.70M$392.80M(m)
2014-12-31$1.29B(m)$242.50M$381.30M$185.10M(m)
2013-12-31$1.12B(m)$299.35M$394.01M$104.34M(m)
2012-12-31$916.08M(m)$173.39M$201.75M$136.23M(m)
2011-12-31$743.18M(m)$180.01M$156.48M$81.87M(m)
2010-12-31$592.90M(m)$165.31M$188.61M$43.95M(m)
2009-12-31$358.88M(m)$120.37M$171.89M-$695.00K(m)
2008-12-31$281.50M(m)$239.18M$94.31M-$34.39M(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viatris Inc (VTRS)United States$20.008B-0.00
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17